---
title: Molecular Diagnostics
order: 5
category: Clinical Pathology
status: complete
last_updated: '2025-01-09'
---

# Molecular Diagnostics

## Overview

Molecular diagnostics is the field of laboratory medicine that analyzes nucleic acids (DNA, RNA) and proteins at the molecular level to diagnose disease, guide treatment, monitor therapeutic response, and assess prognosis. This rapidly evolving discipline has revolutionized medicine by enabling precision diagnosis, personalized therapy, early disease detection, and pharmacogenomic optimization. Molecular diagnostics encompasses infectious disease testing, genetic disorder diagnosis, cancer genomics, prenatal screening, and companion diagnostics for targeted therapies.

### Scope of Practice
- Nucleic acid amplification and detection (PCR, real-time PCR)
- DNA sequencing and mutation analysis (Sanger, next-generation sequencing)
- Cytogenetics and fluorescence in situ hybridization (FISH)
- Microarray technology and gene expression profiling
- Pharmacogenomics and personalized medicine
- Infectious disease molecular testing
- Cancer genomics and minimal residual disease monitoring
- Prenatal and preimplantation genetic testing

### Clinical Significance
- Early and accurate disease diagnosis
- Identification of genetic risk factors
- Selection of targeted therapies
- Monitoring treatment response and resistance
- Prediction of drug metabolism and toxicity
- Prenatal diagnosis and carrier screening
- Infectious disease detection and characterization

## Fundamental Concepts

### Central Dogma of Molecular Biology
- **DNA → RNA → Protein**: Information flow
- **Replication**: DNA synthesis (cell division)
- **Transcription**: DNA to RNA
- **Translation**: RNA to protein
- **Mutations**: Changes in DNA sequence affect function

### Types of Nucleic Acids

#### Deoxyribonucleic Acid (DNA)
- **Structure**: Double helix, complementary base pairing (A-T, G-C)
- **Location**: Nucleus (nuclear DNA), mitochondria (mtDNA)
- **Function**: Genetic information storage
- **Stability**: Relatively stable, long-term storage

#### Ribonucleic Acid (RNA)
- **Structure**: Single-stranded, ribose sugar, uracil instead of thymine
- **Types**: mRNA (messenger), rRNA (ribosomal), tRNA (transfer), microRNA
- **Function**: Protein synthesis, gene regulation
- **Stability**: Less stable than DNA, requires special handling

### Genetic Variation

#### Single Nucleotide Polymorphisms (SNPs)
- **Definition**: Single base pair changes
- **Frequency**: Most common variation (~1 per 300 bp)
- **Clinical significance**: Drug metabolism, disease susceptibility
- **Examples**: Factor V Leiden, HLA-B*5701 (abacavir hypersensitivity)

#### Insertions and Deletions (Indels)
- **Definition**: Addition or removal of nucleotides
- **Frameshift**: Indels not divisible by 3, alter reading frame
- **Examples**: Cystic fibrosis (ΔF508), thalassemias

#### Copy Number Variations (CNVs)
- **Definition**: Deletions or duplications of DNA segments
- **Size**: 1 kb to several Mb
- **Clinical significance**: DiGeorge syndrome, Prader-Willi/Angelman syndromes
- **Detection**: Array CGH, MLPA, NGS

#### Chromosomal Abnormalities
- **Numerical**: Aneuploidy (trisomies, monosomies)
- **Structural**: Translocations, inversions, deletions, duplications
- **Examples**: Down syndrome (trisomy 21), BCR-ABL1 fusion (CML)

## Molecular Techniques

### Nucleic Acid Extraction

#### DNA Extraction
- **Sources**: Blood, tissue, saliva, buccal swabs
- **Methods**: Organic extraction, solid-phase extraction, magnetic beads
- **Quality assessment**: Concentration, purity (A260/A280 ratio ~1.8)
- **Storage**: -20°C for short-term, -80°C for long-term

#### RNA Extraction
- **Challenges**: RNase contamination, instability
- **Special precautions**: RNase-free reagents and equipment
- **Quality assessment**: Concentration, integrity (RIN score)
- **Storage**: -80°C with RNase inhibitors

### Polymerase Chain Reaction (PCR)

#### Principles
- **Exponential amplification**: 2^n copies after n cycles
- **Components**: Template DNA, primers, dNTPs, DNA polymerase, buffer
- **Temperature cycling**: Denaturation (94-96°C), annealing (50-65°C), extension (72°C)
- **Specificity**: Primer design determines target

#### Standard PCR
- **Applications**: Gene detection, mutation screening, cloning
- **Detection**: Agarose gel electrophoresis
- **Limitations**: End-point analysis, semi-quantitative

#### Real-Time PCR (qPCR)

##### Principles
- **Real-time monitoring**: Fluorescence detection during amplification
- **Quantitative**: Ct (cycle threshold) value inversely proportional to initial template
- **Fluorescent probes**: SYBR Green (non-specific), TaqMan (specific)
- **Standard curve**: Absolute quantification
- **ΔΔCt method**: Relative quantification

##### Applications
- **Viral load monitoring**: HIV, HCV, HBV, CMV
- **Gene expression**: mRNA quantification
- **Copy number analysis**: Gene amplification/deletion
- **Minimal residual disease**: Leukemia monitoring (BCR-ABL1)
- **Pathogen detection**: Rapid identification

##### Advantages
- **Wide dynamic range**: 7-8 logs
- **High sensitivity**: Single copy detection possible
- **Quantitative**: Precise measurement
- **High throughput**: 96-384 well formats

#### Reverse Transcription PCR (RT-PCR)
- **Purpose**: Amplify RNA targets
- **Process**: RNA → cDNA (reverse transcriptase) → PCR
- **Applications**: Gene expression, viral RNA detection
- **Quantitative RT-PCR**: Combine with real-time PCR

#### Multiplex PCR
- **Definition**: Multiple targets in single reaction
- **Advantages**: Cost-effective, specimen conservation
- **Challenges**: Primer interactions, optimization
- **Applications**: Respiratory pathogen panels, STI testing

#### Digital PCR
- **Principle**: Partition samples into thousands of reactions
- **Absolute quantification**: No standard curve needed
- **High precision**: Low abundance targets
- **Applications**: Copy number variation, rare mutation detection

### DNA Sequencing

#### Sanger Sequencing

##### Principles
- **Dideoxy chain termination**: ddNTPs halt synthesis
- **Fluorescent detection**: Four colors for A, C, G, T
- **Capillary electrophoresis**: Size separation
- **Gold standard**: High accuracy (99.9%)

##### Applications
- **Single gene disorders**: CFTR (cystic fibrosis), HBB (sickle cell)
- **Mutation confirmation**: Validate NGS findings
- **Targeted sequencing**: Known mutation hotspots
- **Fragment analysis**: Microsatellite instability, chimerism

##### Limitations
- **Low throughput**: One sequence per reaction
- **Labor intensive**: Multiple reactions for large genes
- **Sensitivity**: Requires 15-20% mutant allele fraction
- **Cost**: Expensive for large-scale sequencing

#### Next-Generation Sequencing (NGS)

##### Platforms
- **Illumina**: Sequencing by synthesis, short reads (150-300 bp)
- **Ion Torrent**: Semiconductor technology, short reads
- **PacBio**: Single-molecule real-time, long reads (10-15 kb)
- **Oxford Nanopore**: Real-time sequencing, ultra-long reads (>100 kb)

##### Workflow
1. **Library preparation**: Fragment DNA, add adapters
2. **Clonal amplification**: Bridge PCR or emulsion PCR
3. **Sequencing**: Massively parallel reactions
4. **Data analysis**: Base calling, alignment, variant calling
5. **Interpretation**: Clinical significance assessment

##### Approaches

###### Targeted Gene Panels
- **Design**: Selected genes for specific conditions
- **Examples**: Cancer panels (50-500 genes), cardiac panels
- **Coverage**: High depth (>500×)
- **Advantages**: Cost-effective, focused analysis, high sensitivity
- **Turnaround time**: 1-2 weeks

###### Whole Exome Sequencing (WES)
- **Target**: All protein-coding regions (~1-2% of genome)
- **Size**: ~30 Mb, 20,000 genes
- **Coverage**: 100-150× average
- **Applications**: Rare disease diagnosis, variant discovery
- **Diagnostic yield**: 25-30% in undiagnosed cases

###### Whole Genome Sequencing (WGS)
- **Target**: Entire genome (~3 billion base pairs)
- **Coverage**: 30-50× (clinical), >100× (research)
- **Advantages**: Detects all variant types, non-coding regions
- **Challenges**: Data storage, interpretation, cost
- **Applications**: Comprehensive diagnosis, structural variants, pharmacogenomics

##### Bioinformatics Analysis
- **Quality control**: Base quality scores, read depth
- **Alignment**: Map reads to reference genome
- **Variant calling**: Identify differences from reference
- **Annotation**: Gene, transcript, functional prediction
- **Filtering**: Remove artifacts, common variants
- **Interpretation**: Clinical significance (pathogenic, benign, VUS)

##### Variant Classification (ACMG Guidelines)
- **Pathogenic**: Disease-causing, well-established
- **Likely pathogenic**: Strong evidence, not definitive
- **Variant of uncertain significance (VUS)**: Insufficient evidence
- **Likely benign**: Evidence against pathogenicity
- **Benign**: Not disease-causing

### Fluorescence In Situ Hybridization (FISH)

#### Principles
- **Fluorescent probes**: Complementary to target sequence
- **Hybridization**: Probe binds to specific chromosomal location
- **Visualization**: Fluorescence microscopy
- **Single-cell resolution**: Detects mosaicism

#### Probe Types
- **Locus-specific**: Target specific genes (HER2, BCR-ABL1)
- **Centromeric**: Identify specific chromosomes (aneuploidy)
- **Whole chromosome painting**: Entire chromosome detection
- **Break-apart probes**: Detect translocations/rearrangements

#### Applications
- **Hematologic malignancies**: BCR-ABL1, PML-RARA, MYC rearrangements
- **Solid tumors**: HER2 amplification (breast), ALK rearrangement (lung)
- **Prenatal diagnosis**: Aneuploidy screening (13, 18, 21, X, Y)
- **Microdeletion syndromes**: DiGeorge (22q11.2), Williams (7q11.23)

#### Advantages and Limitations
- **Advantages**: Rapid (24-48 hours), single-cell analysis, archival tissue
- **Limitations**: Limited targets per assay, requires known target, subjective

### Chromosomal Microarray Analysis (CMA)

#### Types

##### Array Comparative Genomic Hybridization (aCGH)
- **Principle**: Compare patient and reference DNA
- **Detection**: Copy number gains and losses
- **Resolution**: 50-100 kb deletions/duplications
- **Limitation**: Cannot detect balanced rearrangements

##### Single Nucleotide Polymorphism (SNP) Array
- **Principle**: Genotype thousands of SNPs
- **Detection**: Copy number variants and loss of heterozygosity
- **Advantage**: Detects uniparental disomy, consanguinity
- **Application**: Cancer (acquired CNVs, LOH)

#### Clinical Applications
- **First-tier test**: Developmental delay, autism, congenital anomalies
- **Prenatal diagnosis**: Unexplained abnormal ultrasound
- **Cancer**: Acquired chromosomal aberrations
- **Diagnostic yield**: 15-20% in neurodevelopmental disorders

### Gene Expression Profiling

#### Microarray Technology
- **Principle**: Hybridization to thousands of probes simultaneously
- **Applications**: Cancer classification, prognosis, therapy selection
- **Examples**: Oncotype DX (breast cancer), MammaPrint, Cologuard

#### RNA Sequencing (RNA-Seq)
- **Advantages**: Whole transcriptome, novel transcript discovery
- **Applications**: Gene expression, fusion detection, isoform analysis
- **Single-cell RNA-Seq**: Individual cell transcriptomes

## Clinical Applications

### Infectious Disease Diagnostics

#### Viral Pathogens

##### Hepatitis Viruses
- **HCV RNA**: Diagnosis, genotype, viral load monitoring
- **HBV DNA**: Chronic infection monitoring, treatment response
- **Quantitative assays**: Guide antiviral therapy

##### Human Immunodeficiency Virus (HIV)
- **HIV RNA viral load**: Treatment monitoring, prognosis
- **Genotype resistance testing**: Identify drug resistance mutations
- **Proviral DNA**: Diagnosis in special circumstances
- **Target**: Undetectable viral load (<20-50 copies/mL)

##### Cytomegalovirus (CMV)
- **CMV DNA**: Transplant monitoring, congenital infection
- **Quantitative PCR**: Preemptive therapy threshold
- **Clinical significance**: Reactivation in immunocompromised

##### Respiratory Viruses
- **Multiplex panels**: Influenza A/B, RSV, SARS-CoV-2, others
- **Rapid turnaround**: 1-2 hours
- **Clinical utility**: Infection control, antiviral decisions

#### Bacterial Pathogens

##### Mycobacterium tuberculosis
- **TB PCR**: Rapid diagnosis from respiratory specimens
- **Rifampin resistance**: Detect rpoB mutations (GeneXpert)
- **Directly observed specimens**: Smear-positive or high clinical suspicion

##### Sexually Transmitted Infections (STI)
- **Chlamydia trachomatis and Neisseria gonorrhoeae**: NAAT testing
- **Specimens**: Urine, genital swabs
- **Sensitivity**: Superior to culture

##### Gastrointestinal Pathogens
- **Multiplex panels**: Bacteria, viruses, parasites
- **Clostridium difficile**: Toxin genes (tcdB)
- **Challenges**: Colonization vs. infection

#### Fungal Pathogens
- **Aspergillus galactomannan**: Serum and BAL
- **Pneumocystis jirovecii**: PCR from BAL
- **Candida**: Blood culture PCR, species identification

### Cancer Diagnostics

#### Hematologic Malignancies

##### Leukemia and Lymphoma Classification
- **Immunophenotyping**: Flow cytometry, immunohistochemistry
- **Cytogenetics**: Karyotype, FISH
- **Molecular**: PCR for specific translocations
- **NGS panels**: Comprehensive mutation profiling

##### Specific Markers

###### BCR-ABL1 (Philadelphia Chromosome)
- **Detection**: RT-PCR, FISH, karyotype
- **Quantification**: International scale (IS) for monitoring
- **Monitoring**: Every 3 months during therapy
- **Major molecular response**: BCR-ABL1 ≤0.1% IS
- **Resistance testing**: ABL1 kinase domain mutations

###### PML-RARA
- **Disease**: Acute promyelocytic leukemia (APL)
- **Detection**: RT-PCR, FISH
- **Monitoring**: Minimal residual disease
- **Treatment**: ATRA, arsenic trioxide

###### JAK2 V617F
- **Diseases**: Polycythemia vera, essential thrombocythemia, primary myelofibrosis
- **Allele burden**: Correlates with phenotype
- **Other mutations**: JAK2 exon 12, CALR, MPL

##### Minimal Residual Disease (MRD)
- **Definition**: Submicroscopic disease detection
- **Methods**: Flow cytometry, PCR, NGS
- **Sensitivity**: 10^-4 to 10^-6 (0.01%-0.0001%)
- **Clinical significance**: Predicts relapse, guides therapy
- **Applications**: ALL, AML, CLL, multiple myeloma

#### Solid Tumors

##### Lung Cancer
- **EGFR mutations**: Exons 19, 21 (tyrosine kinase inhibitors)
- **ALK rearrangements**: FISH, IHC, NGS (crizotinib, alectinib)
- **ROS1 rearrangements**: Similar to ALK
- **PD-L1 expression**: IHC for immunotherapy selection
- **KRAS mutations**: Prognostic, specific inhibitors emerging

##### Colorectal Cancer
- **KRAS/NRAS**: Predict anti-EGFR therapy response
- **BRAF V600E**: Poor prognosis, targeted therapy
- **Microsatellite instability (MSI)**: Lynch syndrome, immunotherapy response
- **Mismatch repair (MMR) deficiency**: IHC for MLH1, MSH2, MSH6, PMS2

##### Breast Cancer
- **HER2 amplification**: FISH, IHC (trastuzumab therapy)
- **Hormone receptors**: ER, PR by IHC
- **Gene expression assays**: Oncotype DX, MammaPrint (prognosis, chemo benefit)
- **PIK3CA mutations**: Alpelisib in advanced disease
- **Germline BRCA1/2**: Hereditary cancer, PARP inhibitors

##### Melanoma
- **BRAF V600E/K**: Vemurafenib, dabrafenib, trametinib
- **NRAS mutations**: 15-20% of melanomas
- **KIT mutations**: Acral and mucosal melanomas
- **PD-L1**: Immunotherapy selection

##### Companion Diagnostics
- **Definition**: Test required for drug approval/use
- **Examples**: HER2 for trastuzumab, EGFR for erlotinib, ALK for crizotinib
- **Regulation**: FDA-approved assays
- **Integration**: Treatment decision algorithms

#### Liquid Biopsy

##### Circulating Tumor DNA (ctDNA)
- **Source**: Tumor-derived cell-free DNA in blood
- **Applications**: Early detection, monitoring, resistance mechanisms
- **Advantages**: Non-invasive, serial sampling, tumor heterogeneity
- **Challenges**: Low abundance, assay sensitivity
- **Clinical use**: Lung cancer EGFR testing, colorectal cancer monitoring

##### Circulating Tumor Cells (CTCs)
- **Enumeration**: Prognostic in metastatic cancer
- **Characterization**: Molecular profiling
- **Challenges**: Rare cells (1 per billion)

### Inherited Disorders

#### Single Gene Disorders

##### Cystic Fibrosis
- **Gene**: CFTR (7q31.2)
- **Mutations**: >2000 known, ΔF508 most common
- **Testing**: Carrier screening, diagnostic, newborn screening
- **Sweat chloride**: Functional test

##### Sickle Cell Disease
- **Gene**: HBB (11p15.5)
- **Mutation**: HbS (Glu6Val)
- **Testing**: Hemoglobin electrophoresis, DNA testing
- **Carrier screening**: High-risk populations

##### Duchenne Muscular Dystrophy
- **Gene**: DMD (Xp21.2)
- **Mutations**: Deletions (60-70%), duplications (10%), point mutations
- **Testing**: MLPA, Sanger sequencing, NGS
- **Carrier screening**: Females with family history

##### Hereditary Cancer Syndromes

###### Hereditary Breast and Ovarian Cancer (HBOC)
- **Genes**: BRCA1 (17q21), BRCA2 (13q13)
- **Lifetime risk**: 45-85% breast, 10-40% ovarian
- **Management**: Enhanced surveillance, prophylactic surgery
- **Treatment**: PARP inhibitors for BRCA-mutated cancers

###### Lynch Syndrome
- **Genes**: MLH1, MSH2, MSH6, PMS2, EPCAM
- **Cancers**: Colorectal, endometrial, others
- **Screening**: MSI/IHC on tumors, then germline testing
- **Surveillance**: Colonoscopy every 1-2 years starting age 20-25

#### Chromosomal Disorders

##### Trisomy 21 (Down Syndrome)
- **Incidence**: 1 in 700 births, increases with maternal age
- **Detection**: Cell-free DNA screening, karyotype confirmation
- **Features**: Intellectual disability, cardiac defects, characteristic facies

##### Turner Syndrome
- **Karyotype**: 45,X or mosaicism
- **Features**: Short stature, ovarian dysgenesis
- **Diagnosis**: Karyotype

### Prenatal and Preconception Testing

#### Non-Invasive Prenatal Testing (NIPT)
- **Method**: Cell-free fetal DNA from maternal blood
- **Timing**: 10 weeks gestation and beyond
- **Targets**: Trisomies 21, 18, 13, sex chromosome aneuploidies
- **Sensitivity/Specificity**: >99% for trisomy 21
- **Limitations**: Screening test, requires confirmation

#### Prenatal Diagnostic Testing
- **Chorionic villus sampling (CVS)**: 10-13 weeks
- **Amniocentesis**: 15-20 weeks
- **Karyotype**: Gold standard for chromosome analysis
- **Microarray**: Detect submicroscopic deletions/duplications
- **Confirmation**: Required for positive NIPT

#### Carrier Screening
- **Expanded panels**: 100+ disorders
- **Timing**: Preconception or early pregnancy
- **Interpretation**: Residual risk calculation
- **Common conditions**: CF, SMA, hemoglobinopathies, Tay-Sachs

#### Preimplantation Genetic Testing (PGT)
- **PGT-A**: Aneuploidy screening
- **PGT-M**: Monogenic disorders
- **PGT-SR**: Structural rearrangements
- **Procedure**: Embryo biopsy during IVF

### Pharmacogenomics

#### Drug-Metabolizing Enzymes

##### Cytochrome P450 Enzymes

###### CYP2D6
- **Substrates**: Codeine, tamoxifen, antidepressants, antipsychotics
- **Phenotypes**: Poor, intermediate, extensive, ultrarapid metabolizers
- **Clinical impact**: Codeine inefficacy (PM) or toxicity (UM)
- **Testing**: Genotype predicts phenotype

###### CYP2C19
- **Substrates**: Clopidogrel, proton pump inhibitors, antidepressants
- **Clinical impact**: Clopidogrel reduced efficacy in PMs
- **Alternative**: Prasugrel, ticagrelor (not affected)

###### CYP2C9
- **Substrates**: Warfarin, phenytoin, NSAIDs
- **Impact**: Dose requirements, bleeding risk

##### Thiopurine S-Methyltransferase (TPMT)
- **Substrates**: Azathioprine, 6-mercaptopurine
- **Deficiency**: 0.3% (homozygous), 10% (heterozygous)
- **Impact**: Severe myelosuppression in deficient patients
- **Recommendation**: Test before initiating therapy

#### Drug Targets and Transporters

##### VKORC1
- **Drug**: Warfarin
- **Impact**: Dose requirements
- **Combined**: CYP2C9 and VKORC1 genotypes predict dose

##### HLA-B*5701
- **Drug**: Abacavir (HIV therapy)
- **Impact**: Hypersensitivity reaction (5-8%)
- **Recommendation**: Screen before prescribing (FDA black box)

##### SLCO1B1
- **Drug**: Simvastatin
- **Impact**: Myopathy risk
- **Recommendation**: Consider in high-dose therapy

#### Clinical Implementation
- **Preemptive testing**: Genotype before prescribing
- **Clinical decision support**: Electronic alerts and recommendations
- **Consortia**: CPIC (Clinical Pharmacogenetics Implementation Consortium)
- **Challenges**: Cost, reimbursement, education

## Quality Assurance and Interpretation

### Analytical Validation

#### Performance Characteristics
- **Analytical sensitivity (LOD)**: Lowest detectable level
- **Analytical specificity**: Correct target amplification
- **Accuracy**: Concordance with reference method
- **Precision**: Reproducibility (within-run, between-run)
- **Reportable range**: Validated measurement interval

#### Quality Control
- **Positive controls**: Known positive samples
- **Negative controls**: No template controls
- **Extraction controls**: Monitor extraction efficiency
- **Amplification controls**: Detect inhibition
- **Contamination monitoring**: Prevent false positives

### Clinical Validation

#### Clinical Sensitivity and Specificity
- **Clinical sensitivity**: Positive in disease
- **Clinical specificity**: Negative in health
- **Comparison**: Gold standard or clinical outcomes

#### Proficiency Testing
- **External quality assessment**: CAP, EMQN
- **Frequency**: 2-3 times per year
- **Targets**: Common and challenging samples
- **Performance**: Graded and reviewed

### Result Interpretation

#### Variant Interpretation
- **Population frequency**: Rare in gnomAD database
- **Computational predictions**: In silico tools (SIFT, PolyPhen)
- **Functional studies**: Literature review
- **Segregation**: Co-occurrence with disease in family
- **De novo status**: New mutation in patient
- **ACMG criteria**: Pathogenic, likely pathogenic, VUS, likely benign, benign

#### Clinical Correlation
- **Phenotype matching**: Consistent with clinical presentation
- **Age of onset**: Appropriate timing
- **Mode of inheritance**: Matches family pattern
- **Penetrance**: Variable expression consideration
- **Genetic counseling**: Essential for interpretation

#### Reporting Requirements
- **Gene and variant**: HGVS nomenclature
- **Zygosity**: Heterozygous, homozygous, hemizygous
- **Classification**: Pathogenicity assessment
- **Clinical significance**: Disease association
- **Recommendations**: Testing, surveillance, family screening
- **Limitations**: Test limitations, residual risk

### Ethical and Legal Considerations

#### Informed Consent
- **Purpose**: Test rationale and limitations
- **Results**: Possible findings and implications
- **Secondary findings**: Incidental/actionable variants
- **Family implications**: Cascade testing
- **Psychological impact**: Anxiety, insurance discrimination

#### Secondary Findings
- **ACMG recommendations**: 73 genes for reporting
- **Conditions**: Medically actionable, preventable/treatable
- **Patient choice**: Opt-in or opt-out
- **Examples**: BRCA1/2, Lynch syndrome genes, cardiac conditions

#### Privacy and Discrimination
- **GINA**: Genetic Information Nondiscrimination Act
- **HIPAA**: Health information privacy
- **Direct-to-consumer testing**: Challenges and concerns
- **Data sharing**: Research, databases (ClinVar, gnomAD)

## Emerging Technologies

### Long-Read Sequencing
- **Platforms**: PacBio, Oxford Nanopore
- **Advantages**: Structural variants, repeat regions, phasing
- **Applications**: Complex rearrangements, methylation analysis

### Single-Cell Sequencing
- **DNA sequencing**: Tumor heterogeneity, clonal evolution
- **RNA sequencing**: Cell-type identification, gene expression
- **Applications**: Cancer, immunology, development

### CRISPR-Based Diagnostics
- **SHERLOCK, DETECTR**: Nucleic acid detection
- **Advantages**: Rapid, point-of-care potential
- **Applications**: Infectious disease, SNP detection

### Artificial Intelligence
- **Variant interpretation**: Pathogenicity prediction
- **Image analysis**: Karyotype, FISH interpretation
- **Clinical decision support**: Treatment recommendations

## Key Points

- Molecular diagnostics enables precision medicine through DNA and RNA analysis
- PCR and real-time PCR provide rapid, sensitive nucleic acid detection and quantification
- Next-generation sequencing has revolutionized genetic disease diagnosis and cancer genomics
- FISH detects chromosomal abnormalities at single-cell resolution
- Infectious disease molecular testing provides rapid pathogen identification
- Cancer molecular profiling guides targeted therapy selection
- Pharmacogenomics optimizes drug selection and dosing based on genetic variation
- Prenatal testing includes non-invasive screening and diagnostic confirmation
- Variant interpretation requires integration of multiple evidence sources (ACMG guidelines)
- Ethical considerations include informed consent, secondary findings, and genetic discrimination

## References

1. Buckingham L, Flaws ML. Molecular Diagnostics: Fundamentals, Methods, and Clinical Applications. 3rd ed. FA Davis; 2018.
2. Coleman WB, Tsongalis GJ. Molecular Diagnostics for the Clinical Laboratorian. 2nd ed. Humana Press; 2006.
3. Nussbaum RL, McInnes RR, Willard HF. Thompson & Thompson Genetics in Medicine. 8th ed. Elsevier; 2015.
4. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants. Genet Med. 2015;17(5):405-424.
5. Rehm HL, Bale SJ, Bayrak-Toydemir P, et al. ACMG clinical laboratory standards for next-generation sequencing. Genet Med. 2013;15(9):733-747.
6. NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment. 2024.
7. Clinical Pharmacogenetics Implementation Consortium (CPIC). Guidelines. www.cpicpgx.org. 2024.
8. Kalia SS, Adelman K, Bale SJ, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing. Genet Med. 2017;19(2):249-255.
9. Gregg AR, Skotko BG, Benkendorf JL, et al. Noninvasive prenatal screening for fetal aneuploidy, 2016 update. Obstet Gynecol. 2016;127(5):e123-e137.
10. Tsongalis GJ, Peterson JD, de Abreu FB, et al. Routine use of the Ion Torrent AmpliSeq Cancer Hotspot Panel for identification of clinically actionable somatic mutations. Clin Chem Lab Med. 2014;52(5):707-714.
